Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor added to pegylated interferon alfa-2b and nucleos(t)ide analogs in chronic hepatitis B with poor interferon response
ChiCTR2400091948Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Nov 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: HBsAg clearance at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2400091948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091948.